• Carlos González-Muñoza, Margalida Calafat, Javier P Gisbert, Eva Iglesias, Miguel Mínguez, Beatriz Sicilia, Montserrat Aceituno, Fernando Gomollón, Xavier Calvet, Elena Ricart, Luisa De Castro, Montserrat Rivero, Francisco Mesonero, Lucía Márquez, Pilar Nos, Ainhoa Rodríguez-Pescador, Jordi Guardiola, MarianaFe García-Sepulcre, Santiago García-López, Rufo H Lorente-Poyatos, Cristina Alba, Ramon Sánchez-Ocaña, Isabel Vera, Lucía Madero, Sabino Riestra, Mercedes Navarro-Llavat, Jose L Pérez-Calle, Blau Camps, Van DomselaarManuelMH. U. de Torrejón (Gastroenterology Department, Torrejón de Ardoz, Spain)., Alfredo J Lucendo, Maria Dolores Martín-Arranz, Miguel A Montoro-Huguet, Mónica Sierra-Ausín, Jordina Llaó, Daniel Carpio, Pilar Varela, Olga Merino, Luis I Fernández-Salazar, Marta Piqueras, Eva Sesé, David Busquets, Carlos Tardillo, Nuria Maroto, Joan Riera, Carlos Martínez-Flores, Fernando Muñoz, Jordi Gordillo-Ábalos, Federico Bertoletti, Esther Garcia-Planella, Eugeni Domènech, and ENEIDA project of GETECCU .
• H. Santa Creu i Sant Pau (Gastroenterology Department, Barcelona, Spain).
• Postgrad Med J. 2024 Jun 24.

Background And AimsFamilial inflammatory bowel disease (IBD) history is a controversial prognostic factor in IBD. We aimed to evaluate the impact of a familial history of IBD on the use of medical and surgical treatments in the biological era.MethodsPatients included in the prospectively maintained ENEIDA database and diagnosed with IBD after 2005 were included. Familial forms were defined as those cases with at least one first-degree relative diagnosed with IBD. Disease phenotype, the use of biological agents, or surgical treatments were the main outcomes.ResultsA total of 5263 patients [2627 Crohn's disease (CD); 2636 ulcerative colitis (UC)] were included, with a median follow-up of 31 months. Of these, 507 (10%) corresponded to familial forms. No clinical differences were observed between familial and sporadic IBD forms except a lower age at IBD diagnosis and a higher rate of males in familial forms of UC. In CD, the proportions of patients treated with thiopurines (54.4% vs 46.7%; P = .015) and survival time free of thiopurines (P = .009) were lower in familial forms. No differences were found regarding the use of biological agents. Concerning surgery, a higher rate of intestinal resections was observed in sporadic CD (14.8% vs 9.9%, P = .027). No differences were observed in UC.ConclusionsIn the era of biological therapies, familial and sporadic forms of IBD show similar phenotypes and are managed medically in a similar way; whether these is due to lack of phenotypical differences or an effect of biological therapies is uncertain. What is already known on this topic: IBD's etiopathogenesis points to an interaction between environmental and genetic factors, being familial history a controversial prognostic factor. Biological agents use and need for surgery regarding familial or sporadic forms of IBDs present conflicting results. What this study adds: Familial and sporadic forms of IBD have similar phenotypes and are managed medically and surgically in a similar way. How this study might affect research, practice or policy: Familial aggregation should not be considered a factor associated with more aggressive disease.© The Author(s) 2024. Published by Oxford University Press on behalf of Fellowship of Postgraduate Medicine. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

4 keywords...

hide…